Eczema (Atopic Dermatitis)
main-banner
Eczema (Atopic Dermatitis)
ACT17207 Enrolling

Atopic Dermatitis Research Trial (21 Weeks)


Treatment: Oral Age: 18 Years

Adults aged 18 or older with a history of atopic dermatitis (AD) for at least 12 months, may qualify to participate. Individuals must have moderate to severe disease involving 10% or more body surface area. Documentation of inadequate response or intolerance to topical corticosteroids (TCS) within 6 months prior to study entry, is also required.

Participants will receive investigational oral medication (active study drug) or placebo, in tablet form.; Study medication and study-related assessments will be provided at no cost. Reimbursement for study-related expenses may be provided.

Study participation will last about 21 weeks and involve about 8 visits to the study centre.


The following information is from ClinicalTrials.gov

Last Update Posted: November 27, 2022

Official Title

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Proof-of-concept Study Evaluating Efficacy and Safety of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Who Are Inadequate Responders or Intolerant to Topical Corticosteroids

ClinicalTrials.gov ID

NCT05018806

Sponsor

Sanofi

Study Description

  • Brief Summary:

    This is a parallel, treatment, Phase 2, double-blind, 2-arm, placebo-controlled study with 2 staggered cohorts (2 arms in each cohort) to evaluate the efficacy and safety of rilzabrutinib in adult participants (aged at least 18 years) with moderate-to-severe AD and intolerance or inadequate response to topical corticosteroids (TCS). In parallel to the main study, Japanese participants will be enrolled in a separate sub-study and randomized to receive: Rilzabrutinib TID, Rilzabrutinib BID, or Matching Placebo TID. The total study duration per participant is expected to be approximately 21 weeks, including up to 4 weeks of screening, 16 weeks of on-treatment double-blind period, 1 week of post-treatment follow-up.

  • Condition or Disease:

    Atopic Dermatitis

  • Intervention/Treatment:

    Drug: Rilzabrutinib
    Drug: Placebo
  • Phase:

    Phase 2

  • Ages Eligible for Study:

    18 Years and older (Adult)

  • Sexes Eligible for Study:

    All

Inclusion Criteria:

AD as defined by the American Academy of Dermatology Consensus Criteria.
History of AD for at least 12 months prior to baseline as determined by the Investigator through patient interview.
Eczema Area and Severity Index (EASI) score ≥ 12 at screening and at baseline.
IGA score ≥ 3 (on the 0 to 4 IGA scale) at baseline.
BSA of AD involvement ≥ 10% at baseline.
Documented inadequate response or intolerance to TCS within 6 months prior to baseline visit
Baseline PP-NRS score for maximum itch intensity ≥4.
All contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
For optional substudy only: Willingness to have 2 tape strips for comparison of baseline and treatment response.

Exclusion Criteria:

Skin comorbidities that may interfere with study assessments such as psoriasis, tinea corporis, lupus erythematosus.
Conditions that may predispose the patient to excessive bleeding.
Any other clinically significant disease, condition, or medical history that, in the opinion of the Investigator, would interfere with participant safety, trial evaluations, and/or trial procedures.
Laboratory abnormalities at the screening visit
History of serious infections requiring intravenous therapy with the potential for recurrence (as judged by the Site Investigator and the Sponsor Medical Monitor), with less than 4 weeks interval between resolution of serious infection and first dose of study drug, or currently active moderate to severe infection at Screening (Grade 2 or higher) including active coronavirus disease 2019 (COVID-19).
Live vaccine except Bacille Calmette Guerin-vaccination within 28 days prior to Day 1 or plan to receive one during the trial; Bacille Calmette Guerin-vaccination within 12 months prior to Screening.
COVID-19 vaccine within 14 days prior to Study Day 1.
Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate rilzabrutinib/placebo absorption.
Initiation of prescription moisturizers (with or without additives such as ceramide, hyaluronic acid, urea, or filaggrin), topical anesthetics or antihistamines during the screening period.
Use of TCS, topical calcineurin (tacrolimus, and/or pimecrolimus) or topical phosphodiesterase 4 inhibitor within 1 week prior to baseline and as concomitant medication.
Use of systemic corticosteroids within 4 weeks prior to baseline and as concomitant medication.
Phototherapy for AD or regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks prior to baseline or likely to be required as concomitant procedure during the study.
Use of mycophenolate mofetil, azathioprine, methotrexate, cyclosporine, dapsone, intravenous immunoglobulin (IVIG), Kineret (anakinra), Enbrel (etanercept), or any other immunosuppressant not mentioned in this exclusion criterion within 4 weeks prior to baseline.
Use of infliximab, adalimumab, golimumab, abatacept, tocilizumab, certolizumab, secukinumab, IFN-γ, JAK inhibitors, dupilumab, and any other biologic or targeted-synthetic disease modifier drug not mentioned in this exclusion criterion or in exclusion criterion, as well as plasmapheresis within 12 weeks prior to baseline.
Use of anti-CD20 drugs such as rituximab, ofatumumab, other long-acting biologics within 6 months prior to baseline (or shorter if there is documented B cell reconstitution for anti-CD20 drugs).
Use of proton pump inhibitor drugs such as omeprazole and esomeprazole within 3 days of baseline (it is acceptable to change participant to H2 receptor blocking drugs prior to baseline).
Concomitant use of known systemic strong-to-moderate inhibitors and inducers of cytochrome P450 3A (CYP3A) within 14 days or 5 half-lives (whichever is longer) prior to baseline.
Previous use of a BTK inhibitor.
Has received any investigational drug (or is currently using an investigational device) within the 30 days before baseline, or at least 5 times the respective elimination half-life time (whichever is longer).
Active TB or a history of incompletely treated TB, Quantiferon positive patients, Clinically significant abnormality consistent with prior/active TB infection based upon chest radiograph with at least posterior-anterior view, Suspected extrapulmonary TB infection, or patients at high risk of contracting TB.

The above information is not intended to contain all considerations relevant to a patient’s potential participation in a clinical trial.


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.


Participating Locations

COUNTRY
country-icon
Canada

Participating Experts

Dr. Maxwell Sauder

Dermatologist

Dr. Anatoli Freiman

Dermatologist

Dr. Benjamin Barankin

Dermatologist

Dr. Firouzeh Niakosari

Dermatologist

Dr. Charles Lynde

Dermatologist

You May Also Be Interested In

Similar Trials

No Similar Trials Found
about-icon

Learn More About

Eczema (Atopic Dermatitis)

Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials